Stock Price
237.00
Daily Change
-3.30 -1.37%
Monthly
-8.39%
Yearly
49.48%
Q2 Forecast
229.11

UCB reported EUR2.96B in Operating Expenses for its fiscal semester ending in December of 2025.





Operating Expenses Change Date
Alcon AG USD 2.41B 4M Mar/2026
Almirall EUR 517.4M 32K Dec/2025
Amarin USD 51.48M 113K Dec/2025
argenx SE USD 904M 10.57M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.78B 669M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Orion EUR 302.9M 64.2M Mar/2026
Recordati EUR 384.01M 82.67M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
UCB EUR 2.96B 196M Dec/2025
Unibail Rodamco EUR 646.6M 25.4M Dec/2025